These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17878175)

  • 1. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
    Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
    Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
    J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 4. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
    Zhao Q; Wang YN; Wang B
    Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Campbell TM; Brown CW
    J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibitor-related folliculitis.
    Tangri N; Al Hammadi A; Gerstein W
    Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
    [No Abstract]   [Full Text] [Related]  

  • 7. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
    Rojo F; Tabernero J; Albanell J; Van Cutsem E; Ohtsu A; Doi T; Koizumi W; Shirao K; Takiuchi H; Ramon y Cajal S; Baselga J
    J Clin Oncol; 2006 Sep; 24(26):4309-16. PubMed ID: 16963731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acneiform reaction to erlotinib.
    Schalock PC; Zug KA
    Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
    Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acneiforme rash in woman with pulmonary adenocarcinoma].
    Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
    Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib-induced scalp perifolliculitis.
    Rallis E; Petronic-Rosic V; Korfitis C
    Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.